STXS

Stereotaxis, Inc. 10-Q Summary: Period Ended September 30, 2005

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2005, and the nine-month period ended on that date. Stereotaxis, Inc. designs, manufactures, and markets the NIOBE cardiology magnet system, an advanced instrument control system for interventional cardiology procedures. The company is in the early stages of commercialization, relying on collaborations with major medical device manufacturers (Siemens, Philips, J&J) for system integration and marketing.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Volatility: Revenue for the three months ended September 30, 2005, dropped 70% compared to the same period in 2004 ($1.69M vs. $5.71M), driven by a significant decrease in the number of systems delivered. However, for the nine-month period, revenue increased slightly by 2% ($12.92M vs. $12.70M) due to higher average selling prices of the advanced NIOBE II system.
• Expense Increases: Operating expenses rose significantly. General and Administrative (G&A) expenses increased 108% quarter-over-quarter and 82% year-to-date, attributed to commercialization activities, clinical trials, and public company compliance costs. Sales and Marketing expenses increased 65% quarter-over-quarter.
• One-Time Settlement: The nine-month 2005 period included a $2.92 million royalty settlement expense related to a patent licensing dispute with the University of Virginia, which did not occur in the prior year.
• Liquidity Position: Cash and cash equivalents decreased from $16.9 million at year-end 2004 to $6.4 million at September 30, 2005. Total investments decreased from $34.6 million to $15.9 million as the company utilized funds for operations and working capital.

Guidance, Outlook, and Risks

Outlook and Capital Resources: Management expects to continue funding operations through existing cash resources, investments, and credit facilities. The company anticipates continued operating losses in 2005 and 2006 as it scales sales and marketing. In November 2005 (post-period), the company secured a $20 million unsecured borrowing commitment and amended its working capital line of credit to $10 million.

Key Risks and Contingencies:

• Commercialization Dependence: Success relies heavily on collaborations with Siemens, Philips, and J&J. Delays in integration or lack of partner support could materially harm revenue.
• Regulatory Approvals: Future growth depends on FDA clearances for new disposable interventional devices. Delays or denials would limit market expansion.
• Market Adoption: The product is a novel, expensive capital equipment purchase. Hospital adoption rates and reimbursement policies from third-party payors remain uncertain.
• Accounting Changes: The company must adopt SFAS No. 123(R) effective January 1, 2006, which will require expensing stock-based compensation, anticipated to increase reported losses.

Investor Verification Checklist

• Revenue Recognition Timing: Verify the backlog of purchase orders and the specific installation schedules, as revenue is recognized upon installation, leading to potential quarterly volatility.
• Collaboration Status: Confirm the progress of technology integration with strategic partners (Siemens, Philips, J&J) and the status of co-marketing efforts.
• Regulatory Pipeline: Review the status of pending FDA 510(k) clearances for new disposable devices, which are critical for recurring revenue.
• Liquidity Runway: Assess the sufficiency of the $22.3 million in liquid assets (cash + short-term investments) against the burn rate of approximately $10 million per quarter in operating cash usage.
• Stock-Based Compensation Impact: Monitor the quantified impact of the upcoming SFAS 123(R) adoption on future net loss figures.